New Zealand markets closed
  • NZX 50

    12,790.16
    -36.83 (-0.29%)
     
  • NZD/USD

    0.6804
    -0.0059 (-0.86%)
     
  • NZD/EUR

    0.5953
    -0.0031 (-0.52%)
     
  • ALL ORDS

    7,717.10
    -80.40 (-1.03%)
     
  • ASX 200

    7,393.90
    -80.50 (-1.08%)
     
  • OIL

    84.27
    +2.15 (+2.62%)
     
  • GOLD

    1,817.30
    -4.10 (-0.23%)
     
  • NASDAQ

    15,611.59
    +115.98 (+0.75%)
     
  • FTSE

    7,542.95
    -20.90 (-0.28%)
     
  • Dow Jones

    35,911.81
    -201.81 (-0.56%)
     
  • DAX

    15,883.24
    -148.35 (-0.93%)
     
  • Hang Seng

    24,383.32
    -46.45 (-0.19%)
     
  • NIKKEI 225

    28,124.28
    -364.85 (-1.28%)
     
  • NZD/JPY

    77.6800
    -0.6520 (-0.83%)
     

Beckley Psytech to attend 11th Annual LifeSci Partners Virtual Corporate Access Event

·2-min read
  • CEO to participate in a panel discussion on the topic of "Psychedelics: More Than Just a Trip" – January 5, 2022 at 10:00 am ET / 3:00 pm GMT

OXFORD, England, December 08, 2021--(BUSINESS WIRE)--Beckley Psytech, a private company dedicated to addressing neurological and psychiatric disorders through the novel application of psychedelic medicines, today announces that it will attend the 11th Annual LifeSci Partners Corporate Access Event, being held virtually from January 5th to 7th, 2022.

Cosmo Feilding Mellen, CEO of Beckley Psytech, will participate in a panel discussion on the topic of "Psychedelics: More Than Just a Trip" on Wednesday, January 5th at 10:00 am ET / 3:00 pm GMT.

Please register for the event and confirm your interest in meeting with Beckley Psytech management here.

The LifeSci Corporate Access Event will feature innovative privately held and publicly traded biotechnology, medical technology, pharmaceutical, life sciences, and digital health companies from across the globe. The event will include meetings with company senior management teams and panel discussions featuring KOLs, CEOs, specialized investors, and healthcare experts, highlighting the most relevant topics impacting today’s life sciences industry.

-Ends-

Beckley Psytech - www.beckleypsytech.com

Beckley Psytech is a clinical-stage privately held company dedicated to helping patients suffering from neurological and psychiatric disorders by developing a broad pipeline of psychedelic compounds in rare and more common diseases. Our vision is for clinically validated psychedelic medicines to be integrated into modern medical practice in order to help patients with high unmet medical need around the world suffering from Short-lasting unilateral neuralgiform headache attacks (SUNHA), treatment-resistant depression, and other profoundly debilitating conditions. Beckley Psytech was founded in 2019 leveraging some of the expertise developed over more than 20 years by the Beckley Foundation, an independent non-profit and world leader in psychedelic medicine research, and is based out of Oxford, United Kingdom.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211207006217/en/

Contacts

Beckley Psytech
Cosmo Feilding Mellen
Chief Executive Officer
info@beckleypsytech.com

Communications
FTI Consulting
Ben Atwell / Mike Trace
+44 (0)20 3727 1000
beckleypsytech@fticonsulting.com

Investor Relations
LifeSci Advisors
Guillaume van Renterghem
+41 76 735 01 31
gvanrenterghem@lifesciadvisors.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting